Clinical Focus ›› 2024, Vol. 39 ›› Issue (2): 177-182.doi: 10.3969/j.issn.1004-583X.2024.02.016
Previous Articles Next Articles
-
Received:2023-06-01Online:2024-02-20Published:2024-04-18
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.02.016
| [1] |
Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18018.
doi: 10.1038/nrdp.2018.18 pmid: 29644995 |
| [2] |
Liberal R, De Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis[J]. Lancet Gastroenterol Hepatol, 2021, 6(4): 315-326.
doi: 10.1016/S2468-1253(20)30328-9 URL |
| [3] |
Cheng Z, Yang L, Chu H. The gut microbiota: A novel player in autoimmune hepatitis[J]. Front Cell Infect Microbiol, 2022, 12: 947382.
doi: 10.3389/fcimb.2022.947382 URL |
| [4] |
Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577.
doi: 10.1136/gutjnl-2018-317836 pmid: 31201284 |
| [5] |
Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577.
doi: S0168-8278(19)30604-X pmid: 31622696 |
| [6] |
Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature[J]. Int J Mol Sci, 2019, 20(2):395.
doi: 10.3390/ijms20020395 URL |
| [7] |
Medina-Cleghorn D, Nomura DK. Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms[J]. Chem Biol, 2014, 21(9): 1171-1184.
doi: 10.1016/j.chembiol.2014.07.007 URL |
| [8] |
Luan J, Zhang X, Wang S, et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated conA-induced hepatitis[J]. Front Immunol, 2018, 9: 758.
doi: 10.3389/fimmu.2018.00758 pmid: 29692782 |
| [9] |
Vuerich M, Wang N, Kalbasi A, et al. Dysfunctional immune regulation in autoimmune hepatitis: From pathogenesis to novel therapies[J]. Front Immunol, 2021, 12: 746436.
doi: 10.3389/fimmu.2021.746436 URL |
| [10] |
Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine[J]. Annu Rev Immunol, 2020, 38: 23-48.
doi: 10.1146/annurev-immunol-070119-115104 pmid: 32340570 |
| [11] |
Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease[J]. Trends Mol Med, 2016, 22(6): 458-478.
doi: S1471-4914(16)30007-7 pmid: 27178527 |
| [12] |
Rajili'c-Stojanovi'c M, De Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota[J]. FEMS Microbiol Rev, 2014, 38(5): 996-1047.
doi: 10.1111/1574-6976.12075 URL |
| [13] |
Terjung B, Söhne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ[J]. Gut, 2010, 59(6): 808-816.
doi: 10.1136/gut.2008.157818 pmid: 19951907 |
| [14] |
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128.
doi: 10.1038/nrgastro.2017.119 pmid: 29018272 |
| [15] |
Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: A comprehensive review[J]. J Autoimmun, 2013, 46: 97-111.
doi: 10.1016/j.jaut.2013.06.013 pmid: 23891169 |
| [16] |
Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1417-1428.
doi: 10.1111/apt.v51.12 URL |
| [17] |
Wang H, Banerjee N, Liang Y, et al. Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity[J]. Toxicol Appl Pharmacol, 2021, 424: 115597.
doi: 10.1016/j.taap.2021.115597 URL |
| [18] |
Yuksel M, Wang Y, Tai N, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation[J]. Hepatology, 2015, 62(5): 1536-1550.
doi: 10.1002/hep.27998 URL |
| [19] |
Elsherbiny NM, Rammadan M, Hassan EA, et al. Autoimmune hepatitis: Shifts in gut microbiota and metabolic pathways among egyptian patients[J]. Microorganisms, 2020, 8(7):1011.
doi: 10.3390/microorganisms8071011 URL |
| [20] |
Lou J, Jiang Y, Rao B, et al. Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J]. Front Cell Infect Microbiol, 2020, 10: 342.
doi: 10.3389/fcimb.2020.00342 URL |
| [21] |
Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric crohn's disease[J]. Cell Host Microbe, 2015, 18(4): 489-500.
doi: 10.1016/j.chom.2015.09.008 pmid: 26468751 |
| [22] |
Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin regIIIgamma promotes the spatial segregation of microbiota and host in the intestine[J]. Science, 2011, 334(6053): 255-258.
doi: 10.1126/science.1209791 pmid: 21998396 |
| [23] |
Bouskra D, Brézillon C, Bérard M, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis[J]. Nature, 2008, 456(7221): 507-510.
doi: 10.1038/nature07450 |
| [24] |
Kim MH, Kang SG, Park JH, et al. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice[J]. Gastroenterology, 2013, 145(2): 396-406.e1-10.
doi: 10.1053/j.gastro.2013.04.056 pmid: 23665276 |
| [25] |
Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon[J]. Cancer Res, 2009, 69(7): 2826-2832.
doi: 10.1158/0008-5472.CAN-08-4466 pmid: 19276343 |
| [26] |
Su ZQ, Mo ZZ, Liao JB, et al. Usnic acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress[J]. Int Immunopharmacol, 2014, 22(2): 371-378.
doi: 10.1016/j.intimp.2014.06.043 URL |
| [27] |
Pradere JP, Troeger JS, Dapito DH, et al. Toll-like receptor 4 and hepatic fibrogenesis[J]. Semin Liver Dis, 2010, 30(3): 232-244.
doi: 10.1055/s-0030-1255353 URL |
| [28] |
Guo S, Nighot M, Al-Sadi R, et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88[J]. J Immunol, 2015, 195(10): 4999-5010.
doi: 10.4049/jimmunol.1402598 pmid: 26466961 |
| [29] |
Kremer M, Hines IN, Milton RJ, et al. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis[J]. Hepatology, 2006, 44(1): 216-227.
pmid: 16799967 |
| [30] |
Zhou YQ, Weng XF, Dou R, et al. Betulin from hedyotis hedyotidea ameliorates concanavalin A-induced and T cell-mediated autoimmune hepatitis in mice[J]. Acta Pharmacol Sin, 2017, 38(2): 201-210.
doi: 10.1038/aps.2016.102 |
| [31] |
Henao-Mejia J, Elinav E, Thaiss CA, et al. Inflammasomes and metabolic disease[J]. Annu Rev Physiol, 2014, 76: 57-78.
doi: 10.1146/annurev-physiol-021113-170324 pmid: 24274736 |
| [32] |
Bandyopadhyay K, Marrero I, Kumar V. NKT cell subsets as key participants in liver physiology and pathology[J]. Cell Mol Immunol, 2016, 13(3): 337-346.
doi: 10.1038/cmi.2015.115 pmid: 26972772 |
| [33] |
Xue R, Zhang H, Pan J, et al. Peripheral dopamine controlled by gut microbes inhibits invariant natural killer T cell-mediated hepatitis[J]. Front Immunol, 2018, 9: 2398.
doi: 10.3389/fimmu.2018.02398 pmid: 30386344 |
| [34] |
Biagioli M, Carino A, Fiorucci C, et al. GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis[J]. Cell Mol Gastroenterol Hepatol, 2019, 8(3): 447-473.
doi: S2352-345X(19)30081-5 pmid: 31226434 |
| [35] |
Jaruga B, Hong F, Sun R, et al. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: Up-regulating eotaxins and IL-5 and recruiting leukocytes[J]. J Immunol, 2003, 171(6): 3233-3244.
pmid: 12960353 |
| [36] |
Harada K, Isse K, Nakanuma Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction[J]. J Clin Pathol, 2006, 59(2): 184-190.
pmid: 16443736 |
| [37] |
Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes[J]. Nature, 2008, 455(7216): 1109-1113.
doi: 10.1038/nature07336 |
| [38] |
Frantz AL, Rogier EW, Weber CR, et al. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides[J]. Mucosal Immunol, 2012, 5(5): 501-512.
doi: 10.1038/mi.2012.23 pmid: 22491177 |
| [39] |
Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine[J]. Proc Natl Acad Sci U S A, 2009, 106(37): 15813-15818.
doi: 10.1073/pnas.0907722106 URL |
| [40] |
Rehman A, Sina C, Gavrilova O, et al. Nod2 is essential for temporal development of intestinal microbial communities[J]. Gut, 2011, 60(10): 1354-1362.
doi: 10.1136/gut.2010.216259 pmid: 21421666 |
| [41] |
Zhao Y, Alonso C, Ballester I, et al. Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1[J]. Inflamm Bowel Dis, 2012, 18(4): 603-612.
doi: 10.1002/ibd.21851 pmid: 21887730 |
| [42] |
Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis[J]. World J Gastroenterol, 2016, 22(42): 9257-9278.
doi: 10.3748/wjg.v22.i42.9257 URL |
| [43] |
Mizuhara H, O'neill E, Seki N, et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6[J]. J Exp Med, 1994, 179(5): 1529-1537.
doi: 10.1084/jem.179.5.1529 pmid: 8163936 |
| [44] |
Porrett PM, Yuan X, Larosa DF, et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands[J]. J Immunol, 2008, 181(3): 1692-1699.
doi: 10.4049/jimmunol.181.3.1692 pmid: 18641305 |
| [45] |
Vuerich M, Harshe R, Frank LA, et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis[J]. J Hepatol, 2021, 74(1): 48-57.
doi: 10.1016/j.jhep.2020.06.044 pmid: 32663496 |
| [46] |
Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161.
doi: 10.1126/science.aar7201 pmid: 29590047 |
| [47] |
Schiering C, Wincent E, Metidji A, et al. Feedback control of AHR signalling regulates intestinal immunity[J]. Nature, 2017, 542(7640): 242-245.
doi: 10.1038/nature21080 |
| [48] |
Hang S, Paik D, Yao L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation[J]. Nature, 2019, 576(7785): 143-148.
doi: 10.1038/s41586-019-1785-z |
| [49] |
Wang H, Feng X, Yan W, et al. Regulatory T cells in autoimmune hepatitis: Unveiling their roles in mouse models and patients[J]. Front Immunol, 2020, 11: 575572.
doi: 10.3389/fimmu.2020.575572 URL |
| [50] |
Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation[J]. Nature, 2013, 504(7480): 451-455.
doi: 10.1038/nature12726 |
| [51] |
Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system[J]. Nat Rev Immunol, 2017, 17(4): 219-232.
doi: 10.1038/nri.2017.7 pmid: 28260787 |
| [52] |
Liang M, Liwen Z, Jianguo S, et al. Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J]. Front Immunol, 2021, 12: 728723.
doi: 10.3389/fimmu.2021.728723 URL |
| [53] |
Sebode M, Schulz L, Lohse AW. “Autoimmune(-Like)” drug and herb induced liver injury: New insights into molecular pathogenesis[J]. Int J Mol Sci, 2017, 18(9):1954.
doi: 10.3390/ijms18091954 URL |
| [54] |
Grant CR, Holder BS, Liberal R, et al. Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis[J]. Clin Exp Immunol, 2017, 189(1): 71-82.
doi: 10.1111/cei.12956 pmid: 28257599 |
| [55] |
Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A[J]. J Clin Invest, 1992, 90(1): 196-203.
doi: 10.1172/JCI115836 pmid: 1634608 |
| [56] |
Yang Y, Palm NW. Immunoglobulin A and the microbiome[J]. Curr Opin Microbiol, 2020, 56: 89-96.
doi: S1369-5274(20)30099-0 pmid: 32889295 |
| [57] |
Pietrzak B, Tomela K, Olejnik-Schmidt A, et al. Secretory IgA in intestinal mucosal secretions as an adaptive barrier against microbial cells[J]. Int J Mol Sci, 2020, 21(23):9254.
doi: 10.3390/ijms21239254 URL |
| [58] |
Suzuki K, Maruya M, Kawamoto S, et al. The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut[J]. Immunity, 2010, 33(1): 71-83.
doi: 10.1016/j.immuni.2010.07.003 pmid: 20643338 |
| [59] |
Peterson DA, Mcnulty NP, Guruge JL, et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis[J]. Cell Host Microbe, 2007, 2(5): 328-339.
doi: 10.1016/j.chom.2007.09.013 pmid: 18005754 |
| [60] |
Lin H, Lin J, Pan T, et al. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction[J]. Cell Death Dis, 2023, 14(1): 68.
doi: 10.1038/s41419-023-05589-3 pmid: 36709322 |
| [1] | . [J]. Clinical Focus, 2024, 39(1): 84-87. |
| [2] | Yang Zhibin, Shao Yanfang, Pan Li, Yang Yanxia, Yang Yuxi, Zhao Lihui, Zeng Rongkun, Li Yang, Wang Qiaofeng, Wang Cong, Ma Shiwu. Efficacy of magnesium isoglycyrrhizinate in anti-tuberculosis drug-induced liver injury [J]. Clinical Focus, 2021, 36(11): 972-975. |
| [3] | . [J]. Clinical Focus, 2021, 36(9): 856-860. |
| [4] | . [J]. Clinical Focus, 2021, 36(6): 574-576. |
| [5] | . [J]. CLINICAL FOCUS, 2014, 29(2): 202-203. |
| [6] | . [J]. CLINICAL FOCUS, 2013, 28(7): 812-813. |
| [7] | WANG Pu;LIU Jiang-wen;TONG De-feng;CUI Yong. Effects of 15-deoxy-prostaglandin J2 on expression of proliferator-activated receptor γ,tumor necrosis factor-α and interleukin-6 in liver tissue of rats with nonalcoholic fatty liver disease [J]. Clinical Focus, 2013, 28(4): 412-0. |
| [8] | . [J]. Clinical Focus, 2012, 27(22): 1993-1994. |
| [9] | . [J]. Clinical Focus, 2012, 27(18): 1610-1611. |
| [10] | ZHANG Jun-xia;LIU Jun-juan;LI Jia. Clinical characteristics of 42 autoimmune hepatitis patients [J]. Clinical Focus, 2012, 27(12): 1050-1053. |
| [11] | . [J]. Clinical Focus, 2011, 26(24): 2170-2171. |
| [12] | . [J]. CLINICAL FOCUS, 2011, 26(20): 1811-1813. |
| [13] | ZHAO Zhao-xia;YE Li-hong;LU Jian-hua;YANG Li;LIU Yan-chao;LIU Yu-zhen;HOU Jun-liang;DAI Er-hei . Quantification of liver hepatitis B virus covalently closed circular DNA in patients with chronic hepatitia B [J]. CLINICAL FOCUS, 2011, 26(13): 1108-1110. |
| [14] | . [J]. CLINICAL FOCUS, 2010, 25(24): 2174-2174. |
| [15] | . [J]. CLINICAL FOCUS, 2010, 25(23): 2106-2108. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||